- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Cetuximab Induced Hidrocystomas: A Case Report () - Nov 26, 2020 - Abstract #FCPANP2020FCPANP_98; Alternatively, the blockage of the duct may have resulted from inhibition of basal cell migration and increased cell adhesion within the eccrine gland causing accumulation of eccrine gland secretion, and eventually hidrocystomas. To our knowledge, this is the first case describing the resolution of a typical cetuximab-induced acneiform eruption with residual hidrocystomas and milia.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Management of a glottic squamous cell carcinoma with cutaneous metastasis. (Pubmed Central) - Nov 25, 2020 There are limited data about the incidence, diagnostic measures and treatment modalities of glottic cancer with cutaneous metastasis. Our case could provide an important experience to literature by its atypical presentation and treatment-sensitive nature.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer. (Pubmed Central) - Nov 25, 2020 For immuno-OpenPET, Cu-labeled anti-epidermal growth factor receptor antibody cetuximab was intraperitoneally administered into mice...Immuno-OpenPET-guided surgery accurately resected small PC in mice and achieved significantly prolonged survival. This technology could provide a novel diagnostic and therapeutic strategy for small resectable PC to improve patient survival.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
PK/PD data, Journal: In Vivo Pharmacokinetics, Biodistribution and Toxicity of Antibody-Conjugated Gold Nanoparticles in Healthy Mice. (Pubmed Central) - Nov 24, 2020 Cetuximab-conjugated gold nanoparticles are known to target cancer cells, but display toxicity towards normal kidney, liver and endothelial cells in vitro...Furthermore, occasional immune cell infiltration was observed in the lungs. Therefore, we recommend additional in vivo studies, in order to investigate the long-term toxicity and elimination of gold nanoparticles after multiple dosing in their preclinical validation as new targeted anti-cancer therapies.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy (clinicaltrials.gov) - Nov 24, 2020 P2, N=67, Active, not recruiting, Therefore, we recommend additional in vivo studies, in order to investigate the long-term toxicity and elimination of gold nanoparticles after multiple dosing in their preclinical validation as new targeted anti-cancer therapies. Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance. (Pubmed Central) - Nov 22, 2020 We found that EGFR and EGFR in complex with Cetuximab, EGFR , and EGFR in complex with Panitumumab and EGFR in complex with Necitumumab have a weakest binding affinity in comparison to EGFR in complex with the relevant monoclonal antibody. Taken together with the results obtained from docking analysis and MD simulations, the present findings may suggest that, the S492R and V441I mutations confer resistance to Cetuximab, R377S and S447Y mutations mediate resistance to Panitumumab and finally, V441I mutation also confers resistance to Necitumumab.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells. (Pubmed Central) - Nov 21, 2020 We found that AuNP+AG1478 inhibited proliferation more than AG1478 alone; the combination of irradiation+AuNP+AG1478 significantly reduced total cell numbers compared with the combination of irradiation+AuNP; AuNP+AG1478 increased apoptotic reaction to irradiation; the combinations of AuNP+AG1478 and irradiation+AuNP induced more apoptosis than AG1478+irradiation. Whereas AuNP+AG1478 enhanced cytotoxicity in human HNSCC cells by inhibiting proliferation, irradiation+AuNP enhanced cytotoxicity by inducing apoptosis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Transgenic goats producing an improved version of cetuximab in milk. (Pubmed Central) - Nov 21, 2020 This indicates that these goats produce an improved cetuximab version with the potential for enhanced effectiveness and better safety profile compared to treatments with Erbitux. In addition, our study validates transgenic goats as an excellent platform for large-scale production of therapeutic mAbs.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Analysis of cetuximab N-Glycosylation using multiple fractionation methods and capillary electrophoresis mass spectrometry. (Pubmed Central) - Nov 19, 2020 2-AA labelled glycan structures were annotated by CE-MS profiling in combination with exoglycosidase sequencing, revealing potential structures with terminal α-galactose and N-glycolyl-neuraminic acid (NGNA) mainly originating from the Fd fragment. Glycosylation analysis was also performed on different charge variants of Cetuximab that were separated using pH gradient cation-exchange chromatography to investigate the impact of glycosylation on the net charge of the protein.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (clinicaltrials.gov) - Nov 18, 2020 P2, N=35, Active, not recruiting, Impact statement The findings of this analysis, which are consistent with other studies, support that tumour location impacts outcomes in patients with RAS/RAF wt mCRC treated with first-line anti-EGFR therapy and should be considered when choosing SACT for colorectal cancer. Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Nov 17, 2020 P2, N=133, Completed, Trial completion date: Feb 2019 --> Jan 2021 Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Immunogenic cell death: Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. (Pubmed Central) - Nov 14, 2020 The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Phase classification, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2020 P2, N=156, Completed, The antibody, which binds to the dimerization arm of EGFR and inhibits EGFR dimerization, could also overcome TNBC cases with Cetuximab resistance due to ligandindependent activating mutations. Phase classification: P1/2 --> P2
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] An unexpected diagnosis of ectopic pancreas in the liver () - Nov 9, 2020 - Abstract #ECP2020ECP_4560; The evolution was marked by the installation of multiple metastases, which were predominant in the right hepatic lobe, hence, the initiation of neoadjuvant chemotherapy (4 FOLFOX - ERBITUX cures)...Conclusion The diagnosis of heterotopic pancreas prior to surgery is difficult due to its non-specific clinical signs and symptoms. Diagnosis can only be established based on histopathological examination.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] PD-L1 IHC 22C3 pharmDx helps determine first-line pembrolizumab eligibility in head and neck squamous cell carcinoma patients () - Nov 9, 2020 - Abstract #ECP2020ECP_3649; Clinical validation studies show that patients treated with pembrolizumab as a single agent had an overall survival (OS) of 12.3 months at CPS ≥ 1 (95% CI, 10.8-14.3) compared with patients receiving cetuximab, platinum, and 5-fluorouracil (CPS ≥ 1 OS of 10.3 months (95% CI, 9.0-11.5)). Conclusion Analytical and clinical validation studies demonstrate that PD-L1 IHC 22C3 pharmDx is a robust and precise companion diagnostic assay, allowing for selection of eligible HNSCC patients for treatment with pembrolizumab.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] An unexpected diagnosis of ectopic pancreas in the liver () - Nov 9, 2020 - Abstract #ECP2020ECP_2866; The evolution was marked by the installation of multiple metastases, which were predominant in the right hepatic lobe, hence, the initiation of neoadjuvant chemotherapy (4 FOLFOX - ERBITUX cures)...Conclusion The diagnosis of heterotopic pancreas prior to surgery is difficult due to its non-specific clinical signs and symptoms. Diagnosis can only be established based on histopathological examination.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] PD-L1 IHC 22C3 pharmDx helps determine first-line pembrolizumab eligibility in head and neck squamous cell carcinoma patients () - Nov 9, 2020 - Abstract #ECP2020ECP_2084; Clinical validation studies show that patients treated with pembrolizumab as a single agent had an overall survival (OS) of 12.3 months at CPS ≥ 1 (95% CI, 10.8-14.3) compared with patients receiving cetuximab, platinum, and 5-fluorouracil (CPS ≥ 1 OS of 10.3 months (95% CI, 9.0-11.5)). Conclusion Analytical and clinical validation studies demonstrate that PD-L1 IHC 22C3 pharmDx is a robust and precise companion diagnostic assay, allowing for selection of eligible HNSCC patients for treatment with pembrolizumab.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] An unexpected diagnosis of ectopic pancreas in the liver () - Nov 9, 2020 - Abstract #ECP2020ECP_1192; The evolution was marked by the installation of multiple metastases, which were predominant in the right hepatic lobe, hence, the initiation of neoadjuvant chemotherapy (4 FOLFOX - ERBITUX cures)...Conclusion The diagnosis of heterotopic pancreas prior to surgery is difficult due to its non-specific clinical signs and symptoms. Diagnosis can only be established based on histopathological examination.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] PD-L1 IHC 22C3 pharmDx helps determine first-line pembrolizumab eligibility in head and neck squamous cell carcinoma patients () - Nov 9, 2020 - Abstract #ECP2020ECP_620; Clinical validation studies show that patients treated with pembrolizumab as a single agent had an overall survival (OS) of 12.3 months at CPS ≥ 1 (95% CI, 10.8-14.3) compared with patients receiving cetuximab, platinum, and 5-fluorouracil (CPS ≥ 1 OS of 10.3 months (95% CI, 9.0-11.5)). Conclusion Analytical and clinical validation studies demonstrate that PD-L1 IHC 22C3 pharmDx is a robust and precise companion diagnostic assay, allowing for selection of eligible HNSCC patients for treatment with pembrolizumab.
- |||||||||| Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Nov 8, 2020 P1, N=16, Active, not recruiting, Conclusion Analytical and clinical validation studies demonstrate that PD-L1 IHC 22C3 pharmDx is a robust and precise companion diagnostic assay, allowing for selection of eligible HNSCC patients for treatment with pembrolizumab. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
|